No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
ALLK Allakos
- 1.085
- +0.005+0.46%
Trading Apr 16 13:25 ET
95.34MMarket Cap-507P/E (TTM)
1.100High1.000Low184.48KVolume1.070Open1.080Pre Close197.12KTurnover0.32%Turnover RatioLossP/E (Static)87.87MShares5.64052wk High0.56P/B63.04MFloat Cap1.00052wk Low--Dividend TTM58.11MShs Float157.980Historical High--Div YieldTTM9.26%Amplitude1.000Historical Low1.068Avg Price1Lot Size
Intraday
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Hold Rating on Allakos Amidst Cautious Optimism for AK006 Program
Allakos Inc (ALLK) Reports Increased R&D Expenses and Net Loss in Q4
Hold Rating on Allakos Amidst Clinical Pivots and Prospective AK006 Developments
Analysts Are Bullish on These Healthcare Stocks: Allakos (ALLK), Century Therapeutics (IPSC)
Analysts Conflicted on These Healthcare Names: Allogene Therapeutics (ALLO), Aquestive Therapeutics (AQST) and Allakos (ALLK)
TD Cowen Remains a Hold on Allakos (ALLK)
Comments
$Allakos(ALLK.US$ mark my words buyout rumors or news in 2-3 months
still think it will be heading back to price gap
$Allakos(ALLK.US$ Allakos | SC 13G: Statement of acquisition of beneficial ownership by individuals-BlackRock, Inc.(5.8%)
SEC announcement
·
01/29 17:30
SEC announcement
·
01/29 17:30
1
TIMBER!
$Allakos(ALLK.US$ Allakos Announced Topline Data From Its Phase 2 Trial For Lirentelimab In Atopic Dermatitis (ATLAS) And Phase 2B Study In Chronic Spontaneous Urticaria (MAVERICK); The Studies Did Not Meet Their Primary Endpoints
3
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg